ReviewMaterials today. Bio2025
Recent advances in hydrogel-based delivery systems for the treatment of pancreatic cancer.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Review
- Colorectal cancer landscape from gut microbiota: Insights into mutations, epigenetic dysregulation, and immune microenvironment alterations.Virulence · 2026Review
- Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026Review
- An NIR-responsive FeS-loaded alginate hydrogel promotes diabetic wound healing through Nrf2 activation and macrophage polarization.International journal of pharmaceutics: X · 2026Article
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- Nanoimmunomodulation for cartilage repair in osteoarthritis: reprogramming the inflammatory joint microenvironment.International journal of pharmaceutics: X · 2026Review
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A multifunctional hydrogel dressing for wound healing and in vitro cytotoxicity against breast cancer cells: association with GRP78 expression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mediating role of telomere shortening in dioxin-like polychlorinated biphenyls associated cognitive decline in children.Environmental health : a global access science source · 2026Article
- Article
- Hydrogel-Based Platforms for Wound Care: Integrated Strategies for Antimicrobial Delivery and Biofilm Management.Gels (Basel, Switzerland) · 2026Review
- T‑Cell Immunoreceptor with Ig and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains/Cluster of Differentiation 40 Cellular Nanovesicles Carrying Oxaliplatin Exhibited Superior Pancreatic Cancer Cells Therapy.ACS pharmacology & translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a five-year survival rate below 10 %, largely due to late diagnosis, aggressive progression, and intrinsic resistance to conventional therapies. The dense desmoplastic stroma, hypoxic and acidic tumor microenvironment (TME), and profound immunosuppression severely limit drug penetration and efficacy. Hydrogels, as three-dimensional cross-linked polymer networks with high water content, biocompatibility, and tunable physicochemical properties, have emerged as versatile platforms for localized and sustained drug delivery in PDAC. Tailored designs enable hydrogels to respond to TME stimuli, achieving on-demand release and minimizing systemic toxicity. Recent advances demonstrate their utility in delivering chemotherapeutics, immunomodulators, photosensitizers, and gene cargos, as well as serving as scaffolds for tissue engineering and cell therapy. These multifunctional systems enhance intertumoral drug accumulation, remodel the TME, and synergize multimodal therapies to improve antitumor efficacy. Preclinical studies highlight significant tumor suppression and reduced recurrence with favorable safety profiles. However, challenges remain in long-term biosafety, scalable manufacturing, and precise
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.